Association of SOCS6 Gene Polymorphisms and Promoter Hypermethylation With the Progression of Hepatitis B Virus Infection.
| Title: | Association of SOCS6 Gene Polymorphisms and Promoter Hypermethylation With the Progression of Hepatitis B Virus Infection. |
|---|---|
| Authors: | Phuong NV; Institute of Biomedicine and Pharmacy, Vietnam Military Medical University, Hanoi, Vietnam.; 103 Military Hospital, Vietnam Military Medical University, Hanoi, Vietnam.; Dung PV; Institute of Biomedicine and Pharmacy, Vietnam Military Medical University, Hanoi, Vietnam.; 103 Military Hospital, Vietnam Military Medical University, Hanoi, Vietnam.; Nhut LQ; Institute of Biomedicine and Pharmacy, Vietnam Military Medical University, Hanoi, Vietnam.; 103 Military Hospital, Vietnam Military Medical University, Hanoi, Vietnam.; Khanh LV; Institute of Biomedicine and Pharmacy, Vietnam Military Medical University, Hanoi, Vietnam.; Thao TTP; Institute of Biomedicine and Pharmacy, Vietnam Military Medical University, Hanoi, Vietnam.; Hang NT; Department of Pathophysiology, Vietnam Military Medical University, Hanoi, Vietnam.; Ky ND; Pathology and Molecular Biology Center, Vietnam National Cancer Hospital, Hanoi, Vietnam.; Hai NM; 103 Military Hospital, Vietnam Military Medical University, Hanoi, Vietnam.; Khai NX; 103 Military Hospital, Vietnam Military Medical University, Hanoi, Vietnam.; Tien TV; 103 Military Hospital, Vietnam Military Medical University, Hanoi, Vietnam.; Mao CV; Department of Pathophysiology, Vietnam Military Medical University, Hanoi, Vietnam.; Toan NL; Department of Pathophysiology, Vietnam Military Medical University, Hanoi, Vietnam.; Vietnamese-German Center for Medical Research (VG-CARE), 108 Military Central Hospital, Hanoi, Vietnam.; Tong HV; Institute of Biomedicine and Pharmacy, Vietnam Military Medical University, Hanoi, Vietnam.; Department of Pathophysiology, Vietnam Military Medical University, Hanoi, Vietnam.; Vietnamese-German Center for Medical Research (VG-CARE), 108 Military Central Hospital, Hanoi, Vietnam. |
| Source: | International journal of immunogenetics [Int J Immunogenet] 2026 Feb; Vol. 53 (1), pp. 30-40. Date of Electronic Publication: 2025 Nov 01. |
| Publication Type: | Journal Article |
| Language: | English |
| Journal Info: | Publisher: Blackwell Pub Country of Publication: England NLM ID: 101232337 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-313X (Electronic) Linking ISSN: 17443121 NLM ISO Abbreviation: Int J Immunogenet Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: Oxford, UK : Blackwell Pub., c2005- |
| MeSH Terms: | DNA Methylation*/genetics ; Carcinoma, Hepatocellular*/genetics ; Carcinoma, Hepatocellular*/pathology ; Carcinoma, Hepatocellular*/virology ; Liver Neoplasms*/genetics ; Liver Neoplasms*/pathology ; Liver Neoplasms*/virology ; Suppressor of Cytokine Signaling Proteins*/genetics ; Liver Cirrhosis*/genetics ; Liver Cirrhosis*/pathology ; Liver Cirrhosis*/virology ; Hepatitis B, Chronic*/genetics ; Hepatitis B, Chronic*/complications ; Hepatitis B, Chronic*/pathology ; Hepatitis B, Chronic*/virology ; Hepatitis B*/genetics ; Polymorphism, Single Nucleotide*; Promoter Regions, Genetic/genetics ; Hepatitis B virus/pathogenicity ; Humans ; Male ; Female ; Middle Aged ; Genetic Predisposition to Disease ; Disease Progression ; Adult ; Genotype ; Case-Control Studies ; Genetic Association Studies |
| Abstract: | Chronic hepatitis B (CHB) is a major risk factor for liver cirrhosis (LC) and hepatocellular carcinoma (HCC). Genes involved in the JAK/STAT signalling pathway play a critical role in the pathogenesis of HBV-related liver diseases, especially HCC. Although SOCS1 and SOCS3 have been extensively studied, the role of SOCS6 in HBV infection and disease progression remains unclear. This study aimed to investigate the association between SOCS6 gene polymorphisms and promoter methylation with HBV-related liver diseases. This study examined SOCS6 gene polymorphisms in a cohort of 335 patients with HBV-related liver diseases (120 with CHB, 100 with LC and 115 with HCC) and 120 healthy controls (HCs). In addition, SOCS6 promoter methylation was analysed in tumour and adjacent tissues from 41 HCC patients. We found that the rs2062345GA genotype and the dominant genetic model were associated with an increased risk of HBV infection and HCC. The rs7228049GA genotype increased the risk of LC and HCC. Conversely, the rs7228049AA genotype and the recessive model were associated with a reduced risk of CHB, LC and HCC. The SNPs rs2062345, rs7228049 and rs11151580 were related to several clinical parameters such as AST, albumin and prothrombin levels, platelet counts in LC and HCC patients. Promoter hypermethylation of SOCS6 was more prevalent in tumour tissues, especially in larger tumours with poorer histological differentiation (p |
| References: | Banerjee, S., A. Biehl, M. Gadina, S. Hasni, and D. M. Schwartz. 2017. “JAK‐STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects.” Drugs 77, no. 5: 521–546.; Bayle, J., S. Letard, R. Frank, P. Dubreuil, and P. De Sepulveda. 2004. “Suppressor of Cytokine Signaling 6 Associates With KIT and Regulates KIT Receptor Signaling.” Journal of Biological Chemistry 279, no. 13: 12249–12259.; Bruix, J., and M. Sherman. 2011. “American Association for the Study of Liver D. Management of Hepatocellular Carcinoma: An Update.” Hepatology 53, no. 3: 1020–1022.; Cabral, L. K. D., P. A. C. Reyes, L. S. Crocè, C. Tiribelli, and C. H. C. Sukowati. 2021. “The Relevance of SOCS1 Methylation and Epigenetic Therapy in Diverse Cell Populations of Hepatocellular Carcinoma.” Diagnostics 11, no. 10: 1825.; Croker, B. A., H. Kiu, and S. E. Nicholson. 2008. “SOCS Regulation of the JAK/STAT Signalling Pathway.” Seminars in Cell & Developmental Biology 19, no. 4: 414–422.; Dai, C. Y., C. Y. Lin, P. C. Tsai, et al. 2018. “Impact of Tumor Size on the Prognosis of Hepatocellular Carcinoma in Patients Who Underwent Liver Resection.” Journal of the Chinese Medical Association 81, no. 2: 155–163.; Durham, G. A., J. J. L. Williams, M. T. Nasim, and T. M. Palmer. 2019. “Targeting SOCS Proteins to Control JAK‐STAT Signalling in Disease.” Trends in Pharmacological Sciences 40, no. 5: 298–308.; Fléjou, J. F. 2011. “WHO Classification of Digestive Tumors: The Fourth Edition.” Annales De Pathologie 31, no. S5: S27–S31.; Hoan, N. X., H. Van Tong, D. P. Giang, et al. 2017. “SOCS3 Genetic Variants and Promoter Hypermethylation in Patients With Chronic Hepatitis B.” Oncotarget 8, no. 10: 17127–17139.; Hu, Z., J. Yang, Y. Wu, et al. 2014. “Polymorphisms in CISH Gene Are Associated With Persistent Hepatitis B Virus Infection in Han Chinese Population.” PLoS ONE 9, no. 6: e100826.; Jiang, B.‐G., Y. Yang, H. Liu, et al. 2015. “SOCS3 Genetic Polymorphism Is Associated With Clinical Features and Prognosis of Hepatocellular Carcinoma Patients Receiving Hepatectomy.” Medicine 94, no. 40: e1344.; Kabir, N. N., J. Sun, L. Rönnstrand, and J. U. Kazi. 2014. “SOCS6 is a Selective Suppressor of Receptor Tyrosine Kinase Signaling.” Tumor Biology 35: 10581–10589.; Koeberlein, B., A. zur Hausen, N. Bektas, et al. 2010. “Hepatitis B Virus Overexpresses Suppressor of Cytokine Signaling‐3 (SOCS3) Thereby Contributing to Severity of Inflammation in the Liver.” Virus Research 148, no. 1–2: 51–59.; Küçük, C., X. Hu, B. Jiang, et al. 2015. “Global Promoter Methylation Analysis Reveals Novel Candidate Tumor Suppressor Genes in Natural Killer Cell Lymphoma.” Clinical Cancer Research 21, no. 7: 1699–1711.; Lai, R. H., Y. W. Hsiao, M. J. Wang, et al. 2010. “SOCS6, Down‐Regulated in Gastric Cancer, Inhibits Cell Proliferation and Colony Formation.” Cancer Letters 288, no. 1: 75–85.; Lai, R. H., M. J. Wang, S. H. Yang, and J. Y. Chen. 2009. “Genomic Organization and Functional Characterization of the Promoter for the Human Suppressor of Cytokine Signaling 6 Gene.” Gene 448, no. 1: 64–73.; Lei, Z., X. Tang, A. Si, et al. 2020. “microRNA‐454 Promotes Liver Tumor‐Initiating Cell Expansion by Regulating SOCS6.” Experimental Cell Research 390, no. 1: 111955.; Letellier, E., M. Schmitz, K. Baig, et al. 2014. “Identification of SOCS2 and SOCS6 as Biomarkers in Human Colorectal Cancer.” British Journal of Cancer 111, no. 4: 726–735.; Li, Z. B., Z. Z. Li, L. Li, H. T. Chu, and M. Jia. 2015. “MiR‐21 and miR‐183 Can Simultaneously Target SOCS6 and Modulate Growth and Invasion of Hepatocellular Carcinoma (HCC) Cells.” European Review for Medical and Pharmacological Sciences 19, no. 17: 3208–3217.; Lian, J.‐Q., X.‐F. Yang, R.‐R. Zhao, et al. 2014. “Expression Profiles of Circulating Cytokines, Chemokines and Immune Cells in Patients With Hepatitis B Virus Infection.” Hepatitis Monthly 14, no. 6: e18892.; Lin, Y., H. Cao, Y. Tian, et al. 2018. “miR‐24‐3p Stimulates Migration, Invasion and Proliferation of Prostate Cancer Cells by Targeting Suppressor of Cytokine Signaling 6.” International Journal of Clinical and Experimental Pathology 11, no. 3: 1803.; Ouyang, J., T. An, Y. Wang, et al. 2021. “Down‐Regulation of SOCS6: An Unfavorable Prognostic Factor for Gastrointestinal Stromal Tumor Proven by Survival Analysis.” Diagnostic Pathology 16, no. 1: 113.; Papatheodoridis, G. V., H. L. Chan, B. E. Hansen, H. L. Janssen, and P. Lampertico. 2015. “Risk of Hepatocellular Carcinoma in Chronic Hepatitis B: Assessment and Modification With Current Antiviral Therapy.” Journal of Hepatology 62, no. 4: 956–967.; Qiu, X., J. Zheng, X. Guo, et al. 2013. “Reduced Expression of SOCS2 and SOCS6 in Hepatocellular Carcinoma Correlates With Aggressive Tumor Progression and Poor Prognosis.” Molecular and Cellular Biochemistry 378, no. 1‐2: 99–106.; Shinkawa, H., S. Tanaka, D. Kabata, et al. 2021. “The Prognostic Impact of Tumor Differentiation on Recurrence and Survival After Resection of Hepatocellular Carcinoma Is Dependent on Tumor Size.” Liver Cancer 10, no. 5: 461–472.; Song Le, H., V. Q. Binh, D. N. Duy, et al. 2003. “Mannose‐Binding Lectin Gene Polymorphisms and Hepatitis B Virus Infection in Vietnamese Patients.” Mutation Research 522, no. 1‐2: 119–125.; Sriram, K. B., J. E. Larsen, S. M. Savarimuthu Francis, et al. 2012. “Array‐Comparative Genomic Hybridization Reveals Loss of SOCS6 Is Associated With Poor Prognosis in Primary Lung Squamous Cell Carcinoma.” PLoS ONE 7, no. 2: e30398.; Su, M., B. Qin, F. Liu, Y. Chen, and R. Zhang. 2018. “miR‐885‐5p Upregulation Promotes Colorectal Cancer Cell Proliferation and Migration by Targeting Suppressor of Cytokine Signaling.” Oncology Letters 16, no. 1: 65–72.; Sun, X., Y. Sun, J. Li, et al. 2021. “SOCS6 Promotes Radiosensitivity and Decreases Cancer Cell Stemness in Esophageal Squamous Cell Carcinoma by Regulating c‐Kit Ubiquitylation.” Cancer Cell International 21, no. 1: 165.; Tong, H. V., N. L. Toan, H. Song Le, P. G. Kremsner, J. F. Kun, and V. Tp. 2012. “Association of CISH ‐292A/T Genetic Variant With Hepatitis B Virus Infection.” Immunogenetics 64, no. 4: 261–265.; Trengove, M. C., and A. C. Ward. 2013. “SOCS Proteins in Development and Disease.” American Journal of Clinical and Experimental Immunology 2, no. 1: 1–29.; Tunçbilek, S. 2014. “Relationship Between Cytokine Gene Polymorphisms and Chronic Hepatitis B Virus Infection.” World Journal of Gastroenterology 20, no. 20: 6226.; Wang, X. J., D. L. Zhang, C. Fu, B. Z. Wei, and G. J. Li. 2016. “MiR‐183 Modulates Multi‐Drug Resistance in Hepatocellular Cancer (HCC) Cells via miR‐183‐IDH2/SOCS6‐HIF‐1α Feedback Loop.” European Review for Medical and Pharmacological Sciences 20, no. 10: 2020–2027.; Wu, K., G. Hu, X. He, et al. 2013. “MicroRNA‐424‐5p Suppresses the Expression of SOCS6 in Pancreatic Cancer.” Pathology Oncology Research 19, no. 4: 739–748.; Yang, M., H. Chen, L. Zhou, X. Huang, F. Su, and P. Wang. 2020. “Identification of SOCS Family Members With Prognostic Values in Human Ovarian Cancer.” American Journal of Translational Research 12, no. 5: 1824–1838.; Yang, Z., S. Huang, and L. Zhao. 2022. “Suppressor of Cytokine Signaling 6 in Cancer Development and Therapy: Deciphering Its Emerging and Suppressive Roles.” Cytokine & Growth Factor Reviews 64: 21–32.; Ye, C., D. Zhu, J. Lu, X. Zhang, and L. Li. 2016. “The Diagnostic Value of Suppressor of Cytokine Signaling‐1 (SOCS‐1) Methylation for Human Hepatocellular Carcinoma (HCC): A Meta‐Analysis Based on Data From 15 Studies.” International Journal of Clinical and Experimental Medicine 9, no. 8: 15146–15156.; Ye, S., S. Dhillon, X. Ke, A. R. Collins, and I. N. Day. 2001. “An Efficient Procedure for Genotyping Single Nucleotide Polymorphisms.” Nucleic Acids Research 29, no. 17: E88.; Yoon, S., Y. S. Yi, S. S. Kim, J. H. Kim, W. S. Park, and S. W. Nam. 2012. “SOCS5 and SOCS6 Have Similar Expression Patterns in Normal and Cancer Tissues.” Tumour Biology 33, no. 1: 215–221.; Yuan, H., R. Xu, S. Li, et al. 2025. “The Malignant Transformation of Viral Hepatitis to Hepatocellular Carcinoma: Mechanisms and Interventions.” MedComm 6, no. 3: e70121.; Zhang, P., F. Li, N. Li, et al. 2014. “Genetic Variations of SOCS1 Are Associated With Chronic Hepatitis B Virus Infection.” Human Immunology 75, no. 8: 709–714.; Zhang, X., Q. You, X. Zhang, and X. Chen. 2015. “SOCS3 Methylation Predicts a Poor Prognosis in HBV Infection‐Related Hepatocellular Carcinoma.” International Journal of Molecular Sciences 16, no. 9: 22662–22675.; Zheng, H., Y. Yan, J. Cheng, S. Yu, and Y. Wang. 2021. “Association Between SOCS3 Hypermethylation and HBV‐Related Hepatocellular Carcinoma and Effect of Sex and Age: A Meta‐Analysis.” Medicine 100, no. 43: e27604.; Zhi, Y., S. Huang, and Z. Lina. 2022. “Suppressor of Cytokine Signaling 6 in Cancer Development and Therapy: Deciphering Its Emerging and Suppressive Roles.” Cytokine Growth Factor Reviews 64: 21–32. |
| Grant Information: | 108.02-2017.15 Vietnam National Foundation for Science and Technology Development |
| Contributed Indexing: | Keywords: HBV infection; HBV‐related liver diseases; SOCS6; hepatocellular carcinoma; promoter methylation |
| Substance Nomenclature: | 0 (Suppressor of Cytokine Signaling Proteins); 0 (SOCS6 protein, human) |
| Entry Date(s): | Date Created: 20251101 Date Completed: 20260112 Latest Revision: 20260112 |
| Update Code: | 20260130 |
| DOI: | 10.1111/iji.70023 |
| PMID: | 41174995 |
| Database: | MEDLINE |
Journal Article